EBS Collar Strategy
EBS (Emergent BioSolutions Inc.), in the Healthcare sector, (Biotechnology industry), listed on NYSE.
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions.
EBS (Emergent BioSolutions Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $440.1M, a beta of 2.33 versus the broader market, a 52-week range of 5.62-14.06, average daily share volume of 817K, a public-listing history dating back to 2006, approximately 900 full-time employees. These structural characteristics shape how EBS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.33 indicates EBS has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a collar on EBS?
A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot.
Current EBS snapshot
As of June 30, 2026, spot at $8.46, ATM IV 66.10%, IV rank 4.25%, expected move 18.95%. The collar on EBS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this collar structure on EBS specifically: IV regime affects collar pricing on both sides; compressed EBS IV at 66.10% typically pushes the short call premium to roughly offset the long put cost, with a market-implied 1-standard-deviation move of approximately 18.95% (roughly $1.60 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated EBS expiries trade a higher absolute premium for lower per-day decay. Position sizing on EBS should anchor to the underlying notional of $8.46 per share and to the trader's directional view on EBS stock.
EBS collar setup
The EBS collar below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With EBS near $8.46, the first option leg uses a $8.88 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed EBS chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 EBS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $8.46 | long |
| Sell 1 | Call | $8.88 | N/A |
| Buy 1 | Put | $8.04 | N/A |
EBS collar risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium.
EBS collar payoff curve
Modeled P&L at expiration across a range of underlying prices for the collar on EBS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use collar on EBS
Collars on EBS hedge an existing long EBS stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
EBS thesis for this collar
The market-implied 1-standard-deviation range for EBS extends from approximately $6.86 on the downside to $10.06 on the upside. A EBS collar hedges an existing long EBS position with a protective put while financing the put cost via a short call; when the premiums roughly offset, the collar acts as a near-zero-cost insurance band around the current spot. Current EBS IV rank near 4.25% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on EBS at 66.10%. As a Healthcare name, EBS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to EBS-specific events.
EBS collar positions are structurally neutral (protective); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. EBS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move EBS alongside the broader basket even when EBS-specific fundamentals are unchanged. Always rebuild the position from current EBS chain quotes before placing a trade.
Frequently asked questions
- What is a collar on EBS?
- A collar on EBS is the collar strategy applied to EBS (stock). The strategy is structurally neutral (protective): A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot. With EBS stock trading near $8.46, the strikes shown on this page are snapped to the nearest listed EBS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are EBS collar max profit and max loss calculated?
- Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium. For the EBS collar priced from the end-of-day chain at a 30-day expiry (ATM IV 66.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a EBS collar?
- The breakeven for the EBS collar priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current EBS market-implied 1-standard-deviation expected move is approximately 18.95%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a collar on EBS?
- Collars on EBS hedge an existing long EBS stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
- How does current EBS implied volatility affect this collar?
- EBS ATM IV is at 66.10% with IV rank near 4.25%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.